Table 5.
Association of clinical variables with clinical severity
| Variable | Clinical Severity |
Univariate Ordinal Logistic Regression |
Missing | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Home treatment (N=232) | Hospitalization (N=321) | UCI (N=105) | p-value | Adj. p-value | OR | LL | UL | ||
| Male | 99 (42.7%) | 141 (43.9%) | 54 (51.4%) | 0.206 | 0.236 | ||||
| Female | 133 (57.3%) | 180 (56.1%) | 51 (48.6%) | ||||||
| Time onset symptoms | 4.52 (353) | 6.25 (5.04) | 6.61 (4.60) | <0.001 | <0.001 | 1.08 | 1.04 | 1.11 | 2 |
| Age Group | |||||||||
| <50 | 131 (56.5%) | 20 (6.23%) | 1 (0.95%) | ||||||
| 51-60 | 20 (8.62%) | 32 (9.97%) | 11 (10.5%) | <0.001 | <0.001 | 15.85 | 8.11 | 67.15 | |
| 61-70 | 33 (14.2%) | 85 (26.5%) | 21 (20.0%) | <0.001 | <0.001 | 19.41 | 11.12 | 31.89 | |
| 71-80 | 29 (12.5%) | 100 (31.2%) | 37 (35.2%) | <0.001 | <0.001 | 29.60 | 17.04 | 35.16 | |
| >80 | 19 (8.19%) | 84 (26.2%) | 35 (33.3%) | <0.001 | <0.001 | 36.51 | 20.58 | 53.42 | |
| No hypertension | 157 (68.3%) | 101 (31.5%) | 33 (31.4%) | <0.001 | <0.001 | 3.67 | 2.69 | 5.03 | 2 |
| Hypertension | 73 (31.7%) | 220 (68.5%) | 72 (68.6%) | ||||||
| No obesity | 216 (93.5%) | 285 (88.8%) | 91 (86.7%) | 0.028 | 0.037 | 1.72 | 1.06 | 2.78 | 1 |
| Obesity | 15 (6.49%) | 36 (11.2%) | 14 (13.3%) | ||||||
| No diabetes | 201 (86.6%) | 190 (59.2%) | 65 (61.9%) | <0.001 | <0.001 | 2.69 | 1.96 | 3.71 | |
| Diabetes | 31 (13.4%) | 131 (40.8%) | 40 (38.1%) | ||||||
| No asthma | 216 (93.1%) | 312 (97.2%) | 102 (97.1%) | ||||||
| Asthma | 16 (6.90%) | 9 (2.80%) | 3 (2.86%) | ||||||
| No COPD | 214 (94.7%) | 295 (94.2%) | 93 (89.4%) | 0.120 | 0.147 | ||||
| COPD | 12 (5.31%) | 18 (5.75%) | 11 (10.6%) | ||||||
| No smoker | 220 (94.8%) | 303 (94.4%) | 94 (89.5%) | ||||||
| Current Smoker | 12 (5.17%) | 18 (5.61%) | 11 (10.5%) | ||||||
| Never smoked | 229 (98.7%) | 316 (98.4%) | 105 (100%) | 0.006 | 0.009 | 1.98 | 1.22 | 3.22 | |
| Former smoker | 3 (1.29%) | 5 (1.56%) | 0 (0.00%) | ||||||
| No Malignancy | 218 (94.0%) | 286 (89.1%) | 89 (84.8%) | 0.001 | 0.002 | 2.89 | 1.50 | 5.57 | 1 |
| Malignancy | 14 (6.03%) | 35 (10.9%) | 16 (15.2%) | ||||||
| No CVD | 213 (91.8%) | 276 (86.0%) | 83 (79.0%) | 0.001 | 0.002 | 2.06 | 1.34 | 3.18 | |
| CVD | 19 (8.19%) | 45 (14.0%) | 22 (21.0%) | ||||||
| No Cerebrovasc Dis | 225 (97.0%) | 290 (90.3%) | 95 (90.5%) | 0.007 | 0.010 | 2.11 | 1.23 | 3.63 | |
| Cerebrovasc Dis | 7 (3.02%) | 31 (9.66%) | 10 (9.52%) | ||||||
| No CKD | 222 (95.7%) | 298 (92.8%) | 98 (93.3%) | 0.243 | 0.272 | ||||
| CKD | 10 (4.31%) | 23 (7.17%) | 7 (6.67%) | ||||||
| Number of comorbidities | 0.91 (1.27) | 1.85 (1.29) | 2.03 (1.29) | <0.001 | <0.001 | 1.64 | 1.46 | 1.84 | |
COPD: chronic obstructive pulmonary disease; CVD: cardiovascular disease;
Cerebrovasc Dis: cerebrovascular disease; CKD – chronic kidney disease.